olaparib + itraconazole

This combination consists of **olaparib**, a small molecule inhibitor of poly(ADP-ribose) polymerase (PARP) enzymes PARP1 and PARP2, and **itraconazole**, a triazole antifungal agent that is also a potent inhibitor of cytochrome P450 CYP3A4. Olaparib is an approved targeted anticancer therapy primarily used in BRCA-mutated ovarian, breast, pancreatic, and prostate cancers. Itraconazole is approved for systemic and superficial fungal infections but has significant drug–drug interaction potential due to CYP3A4 inhibition. When co-administered, itraconazole increases olaparib systemic exposure approximately 2.7-fold by inhibiting olaparib metabolism via CYP3A4, necessitating dose adjustments and raising the risk of olaparib-associated toxicities. This combination is not an approved therapy but may occur clinically as an example of a pharmacokinetic drug–drug interaction[1][2][3][6].

Brand names

Lynparza (for olaparib)Sporanox (for itraconazole)

Other names

olaparib + itraconazole